Clinical trials: Sadness, open to volunteers
Skin Disease, Immune System Disease
A Study of HL40626S Tablets in Healthy Adults
This is a single-centre, randomized, double-blind, placebo-controlled Phase 1 study to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of HL40626S tablets following single and…
- Conditions
- Skin Disease, Immune System Disease, Skin Diseases, Papulosquamous, Psoriasis (PsO)
- Trial name
- NCT07736586
- Testing
- HL40626S tablets
- Where
- 2 sites in Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- HighsLab Therapeutics Inc.
Alpha-1 Antitrypsin Deficiency
A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD
The purpose of this open-label study is to assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of WVE-006 in participants with alpha-1 antitrypsin deficiency (AATD) following Period 1 single ascending dose…
- Trial name
- NCT06405633
- Testing
- WVE-006
- Where
- 9 sites in Australia, Canada and 4 more
- Volunteers
- 48 people
- Sponsor
- Wave Life Sciences USA, Inc.
Parkinson Disease
First-in-Human Single and Multiple Dose of HL-400
This is a randomized, double-blind, placebo-controlled, dose-escalation study in healthy subjects to evaluate the safety, tolerability, pharmacokinetics of HL-400 (a NLRP3 inhibitor) following oral single and multiple ascending…
- Trial name
- NCT06997484
- Testing
- HL-400
- Where
- United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Highlightll Pharmaceutical (USA) LLC
Seasonal Affective Disorder (SAD)
Virtual Reality Digital Therapeutics for Seasonal Affective Disorder
Seasonal Affective Disorder (SAD) is commonly treated with bright light therapy. Virtual reality (VR) is an immersive computer-generated environment, which has been used to treat mental health difficulties, such as depression…
- Trial name
- VR-SAD (NCT07161570)
- Testing
- Virtual Reality (VR) Intervention, Light Box (LB) intervention
- Volunteers
- 60 people
- Sponsor
- Anglia Ruskin University
Anxiety Disorders, Panic Disorder
Efficacy of Expectancy Focused Exposure Therapy for Anxiety Disorders
This clinical trial evaluates whether an optimized exposure-based treatment improves long-term outcomes for adults with anxiety disorders.
- Conditions
- Anxiety Disorders, Panic Disorder, Social Anxiety Disorder (SAD), Generalised Anxiety Disorder
- Trial name
- EFE-AD (NCT07753330)
- Testing
- Expectancy Focused Exposure, Anxiety Focused Exposure
- Where
- Chile
- Volunteers
- 203 people
- Sponsor
- University of Chile
Idiopathic Pulmonary Fibrosis, Small Airways Disease
Small Airways Disease Functional Assessment in Idiopathic Pulmonary Fibrosis (SWIFT-IPF)
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, fibrosing, and progressive lung disease of unknown cause, whose incidence increases proportionally from the age of 60. It is characterized by a poor prognosis.
- Trial name
- SWIFT-IPF (NCT07312305)
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- University of Milan
Safety, Tolerability
A First-in-Human SAD and MAD Study in HV to Evaluate Oral YR011 Tablet
This is a Phase I clinical trial (protocol number: YR-011-B07) sponsored by Hangzhou Yirui Pharmaceutical Technology Co., Ltd., focusing on the novel oral small-molecule drug YR011 (active ingredient: PA032, a Kv1.3 channel…
- Conditions
- Safety, Tolerability, Pharmacokinetic
- Trial name
- NCT07878481
- Testing
- Kv1.3 potassium channel blocker (PA032, investigational oral small-molecule drug)
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Hangzhou Yirui Pharmaceutical Technology Co., Ltd
Social Anxiety Disorder (SAD)
A Study of NTX-1472 in Social Anxiety Disorder
The primary goal of this Phase 2 clinical trial is to determine the effects of a novel V1a receptor antagonist (NTX-1472) in adults with Social Anxiety Disorder (SAD).
- Trial name
- SOAR (NCT07323784)
- Testing
- NTX-1472
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Newleos Therapeutics, Inc.
Social Anxiety Disorder (SAD), Attention Bias Modification Treatment (ABMT)
Efficacy of Attention Bias Modification vs. Placebo for Social Anxiety Disorder
This study examines whether a computerized attention-training intervention called attention bias modification (ABM) can reduce symptoms of social anxiety disorder (SAD) in adults, and whether symptom improvement is specifically…
- Conditions
- Social Anxiety Disorder (SAD), Attention Bias Modification Treatment (ABMT), Placebo Effect
- Trial name
- NCT07666776
- Testing
- Dot-Probe Attention Bias Modification (ABM)
- Where
- Israel
- Volunteers
- 90 people
- Sponsor
- Tel Aviv University
Social Anxiety Disorder
CvC-SAD (Clinician vs Coach)Self-help Versions in a RCT
Background: Social Anxiety Disorder (SAD) is a common mental problem, where people experience severe and disabling anxiety about social situations and interactions.
- Trial name
- NCT05292612
- Testing
- iCBT(C&W) for SAD
- Where
- Hong Kong
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Healthy Volunteers
SAD and MAD Study of AKB-9090 in Healthy Adult Participants
This is a first-in-human (FIH study designed to evaluate safety, tolerability, pharmacokinetic, and pharmacodynamic effects of AKB-9090 in healthy adult participants.
- Trial name
- NCT07429006
- Testing
- AKB-9090
- Where
- New Zealand
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Akebia Therapeutics
Weight Management in Adult Patients With Obesity or Overweight
Phase I Study of XTL6001 Injection in Healthy and Obese Subjects
This is a multicenter, randomized, double-blind, placebo-controlled Phase I study to evaluate safety, PK and PD of single ascending dose (SAD) and multiple ascending dose (MAD) of XTL6001 injection in healthy and obese adult…
- Trial name
- NCT07205432
- Testing
- XTL6001
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Shanghai Xitaili Biomedicine Technology co., Ltd.
Advanced Solid Tumors
Phase 1 Trial of KH617
KH617 is a injection used for advanced solid tumors which must be diluted with 5% Dextrose Injection.
- Trial name
- NCT05667194
- Testing
- KH617
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Sichuan Honghe Biotechnology Co., Ltd.
Safety Issues, Tolerability
Single Ascending Dose and Multiple Ascending Dose Study of AVR-48
This is a Phase 1 (healthy adult volunteers), 2-part, double-blind, randomized, placebo controlled trial to evaluate the safety and pharmacokinetic (PK) profiles of escalating single doses of AVR-48 versus placebo (SAD) and…
- Conditions
- Safety Issues, Tolerability, Pharmacokinetics, Pharmacodynamics
- Trial name
- NCT06847698
- Testing
- AVR-48
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AyuVis Research, Inc.
Healthy Volunteers
A Phase I Study Comparing the Safety, Pharmacokinetics and Renal Effects of VRP-034 and Marketed Polymyxin B in Healthy Volunteers
This is a Phase 1, single-center, randomized, double-blind, active-controlled clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and nephrotoxicity attenuation potential of VRP-034 compared with…
- Trial name
- VRP-034 (NCT07502144)
- Testing
- VRP-034 (Polymyxin B 500,000 IU), Commercially available Polymyxin B 500,000 IU (Poly-MxB)
- Where
- India
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Venus Remedies Limited
Social Anxiety Disorder (SAD), Oppositional Defiant Disorder
ACTsocially: The (Dis)Similarities of ACT for Changing Internalizing and Externalizing Symptomatology in Adolescence
Social functioning, fundamental to adolescent's development and mental health, may be impaired by polarizing problematic social functioning, namely externalizing symptoms manifested by Oppositional Defiant Disorder and…
- Trial name
- ACTsocially (NCT07456631)
- Testing
- ACTsocially
- Where
- Portugal
- Volunteers
- 54 people
- Sponsor
- University of Coimbra
Parkinson's Disease (PD), Mild to Moderate Parkinson's Disease
A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients.
The goal of this trial is to learn if MTX325 can be developed as a potential disease-modifying treatment for Parkinson's Disease. Parts 1-4 complete, Part 5 (multiple doses in patients with Parkinson's Disease) in progress.
- Conditions
- Parkinson's Disease (PD), Mild to Moderate Parkinson's Disease, Early Stage Parkinson's Disease
- Trial name
- NCT07630545
- Testing
- MTX325
- Where
- 18 sites in Australia, France and 2 more
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Mission Therapeutics
Healthy Volunteers
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986521 in Healthy Participants.
The purpose of this study is to evaluate the safety, tolerability, and drug levels of BMS-986521 following single and multiple ascending doses of BMS-986521 in healthy adult participants, and to evaluate potential food effects on…
- Trial name
- NCT07283263
- Testing
- BMS-985521
- Where
- United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy Volunteers - Male and Female
A Phase I Trial of Subcutaneous QLS7305 in Healthy Adults
The goal of this clinical trial is to evaluate the safety, tolerability, and preliminary characteristics of the investigational drug QLS7305 in healthy adult participants in China.
- Trial name
- NCT07313150
- Testing
- QLS7305 Injection
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Healthy
A Phase 1, SAD and MAD to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral FB-101 in Healthy Adult Male Subjects
This is a Phase 1, randomized, double-blind, placebo-controlled study consisting of SAD and MAD investigation at a single clinical trial center conducted in healthy adult male subjects assessing the safety, tolerability, PK, and…
- Trial name
- NCT07126704
- Testing
- FB-101
- Where
- South Korea
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- 1ST Biotherapeutics, Inc.